| Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma D Liu, B Schilling, D Liu, A Sucker, E Livingstone, L Jerby-Arnon, ... Nature medicine 25 (12), 1916-1927, 2019 | 791 | 2019 |
| Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer M Dietlein, C Kobe, G Kuhnert, S Stockter, T Fischer, K Schomäcker, ... Molecular Imaging and Biology 17, 575-584, 2015 | 399 | 2015 |
| Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches F Dietlein, L Thelen, HC Reinhardt Trends in genetics 30 (8), 326-339, 2014 | 328 | 2014 |
| Identification of cancer driver genes based on nucleotide context F Dietlein, D Weghorn, A Taylor-Weiner, A Richters, B Reardon, D Liu, ... Nature genetics 52 (2), 208-218, 2020 | 241 | 2020 |
| A framework for identification of actionable cancer genome dependencies in small cell lung cancer ML Sos, F Dietlein, M Peifer, J Schöttle, H Balke-Want, C Müller, M Koker, ... Proceedings of the National Academy of Sciences 109 (42), 17034-17039, 2012 | 208 | 2012 |
| PSA-stratified performance of 18F-and 68Ga-PSMA PET in patients with biochemical recurrence of prostate cancer F Dietlein, C Kobe, S Neubauer, M Schmidt, S Stockter, T Fischer, ... Journal of Nuclear Medicine 58 (6), 947-952, 2017 | 190 | 2017 |
| Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer L Meder, P Schuldt, M Thelen, A Schmitt, F Dietlein, S Klein, S Borchmann, ... Cancer research 78 (15), 4270-4281, 2018 | 155 | 2018 |
| A synergistic interaction between Chk1-and MK2 inhibitors in KRAS-mutant cancer F Dietlein, B Kalb, M Jokic, EM Noll, A Strong, L Tharun, L Ozretić, ... Cell 162 (1), 146-159, 2015 | 142 | 2015 |
| Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas S Derks, LK De Klerk, X Xu, T Fleitas, KX Liu, Y Liu, F Dietlein, C Margolis, ... Annals of Oncology 31 (8), 1011-1020, 2020 | 136 | 2020 |
| Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer F Malchers, F Dietlein, J Schöttle, X Lu, L Nogova, K Albus, ... Cancer discovery 4 (2), 246-257, 2014 | 115 | 2014 |
| Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non–small-cell lung cancer NI Vokes, D Liu, B Ricciuti, E Jimenez-Aguilar, H Rizvi, F Dietlein, MX He, ... JCO precision oncology 3, 1-12, 2019 | 112 | 2019 |
| Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer F Dietlein, C Kobe, M Hohberg, BD Zlatopolskiy, P Krapf, H Endepols, ... Journal of Nuclear Medicine 61 (5), 729-734, 2020 | 86 | 2020 |
| A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC F Dietlein, L Thelen, M Jokic, RD Jachimowicz, L Ivan, G Knittel, U Leeser, ... Cancer discovery 4 (5), 592-605, 2014 | 80 | 2014 |
| Genome-wide analysis of somatic noncoding mutation patterns in cancer F Dietlein, AB Wang, C Fagre, A Tang, NJM Besselink, E Cuppen, C Li, ... Science 376 (6589), eabg5601, 2022 | 71 | 2022 |
| The tumour suppressor CYLD regulates the p53 DNA damage response V Fernández-Majada, PS Welz, MA Ermolaeva, M Schell, A Adam, ... Nature communications 7 (1), 12508, 2016 | 66 | 2016 |
| Systematic kinase inhibitor profiling identifies CDK9 as a synthetic lethal target in NUT midline carcinoma J Brägelmann, MA Dammert, F Dietlein, JM Heuckmann, A Choidas, ... Cell reports 20 (12), 2833-2845, 2017 | 53 | 2017 |
| Genome-wide mapping of somatic mutation rates uncovers drivers of cancer MA Sherman, AU Yaari, O Priebe, F Dietlein, PR Loh, B Berger Nature biotechnology 40 (11), 1634-1643, 2022 | 50 | 2022 |
| Integrated molecular drivers coordinate biological and clinical states in melanoma JR Conway, F Dietlein, A Taylor-Weiner, S AlDubayan, N Vokes, ... Nature genetics 52 (12), 1373-1383, 2020 | 45 | 2020 |
| Molecular pathways: exploiting tumor-specific molecular defects in DNA repair pathways for precision cancer therapy F Dietlein, HC Reinhardt Clinical cancer research 20 (23), 5882-5887, 2014 | 45 | 2014 |
| Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer K Golfmann, L Meder, M Koker, C Volz, S Borchmann, L Tharun, ... Oncogene 37 (42), 5682-5693, 2018 | 41 | 2018 |
